In a significant development in the battle against Alzheimer’s disease, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company’s (NYSE:LLY) Alzheimer’s treatment, “Kisunla.”
What Happened: As per the official press release on Tuesday, Kisunla (donanemab-azbt), a once-monthly IV infusion injection, is intended for adults in the early symptomatic stages of Alzheimer’s disease, including those with mild cognitive impairment and mild dementia stage of Alzheimer’s disease, who have confirmed amyloid pathology.
See Also: DentalPlans.com: Empowering Families To Live Healthier Lives ...